Experts discuss future directions for molecular imaging

06/3/2010 | HealthImaging.com

Recent years have seen a significant growth in the use of FDG-PET and FDG-PET/CT in oncologic molecular imaging, particularly in treatment planning, but the future also holds great potential for new PET radiopharmaceuticals, which could allow for precise imaging of drug delivery, said Landis K. Griffeth, director of nuclear medicine at the Baylor University Medical Center in Dallas. The use of FDG in neurology has been less successful because of the difficulty in tissue diagnosis and the dissatisfaction with dementia treatments, but the use of amyloid PET imaging for personalized Alzheimer's disease treatment shows that molecular imaging could eventually be used for preclinical diagnosis of neurological diseases, said Nicolaas I. Bohnen, a radiology and neurology professor at the University of Michigan in Ann Arbor.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX